Mazdutide is a synthetic peptide analogue of oxyntomodulin and the world’s first dual agonist that simultaneously activates the GLP-1 receptor and the glucagon receptor. By activating the GLP-1 receptor, it reduces appetite, enhances satiety, delays gastric emptying, stimulates insulin secretion, and lowers blood glucose levels. Through activation of the glucagon receptor, mazdutide increases energy expenditure, promotes lipolysis, and inhibits hepatic lipogenesis, thereby significantly reducing liver fat content.
In addition to its pronounced weight-loss effects, mazdutide provides comprehensive metabolic benefits, including improved insulin sensitivity, reductions in blood lipid levels, blood pressure, and serum uric acid, as well as a decrease in hepatic fat accumulation.
Research Applications:
- Support metabolic regulation.
- Helps reduce appetite and manage body weight.
- Supports improved glucose control under medical supervision.
- Investigated for broader metabolic and diabetes-related conditions.
